{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T18:31:12Z","timestamp":1786559472744,"version":"build-2736575974"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We evaluated trends in Methicillin-Resistant Staphylococcus aureus (MRSA) hospitalizations and antimicrobial use from 2016 to 2024 across 40\u00a0US children\u2019s hospitals. The rate of MRSA cases per 1000 hospitalizations decreased over time, while the rate of MRSA cases requiring Intensive Care Unit (ICU) care remained constant. There was a marked inter-hospital variability in anti-MRSA antibiotic prescribing.<\/jats:p>","DOI":"10.1093\/jpids\/piag065","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:45:58Z","timestamp":1785843958000},"source":"Crossref","is-referenced-by-count":0,"title":["Trends in Treatment of Methicillin-Resistant\n                    <i>Staphylococcus aureus<\/i>\n                    (MRSA) Infections in Hospitalized Children"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0676-2301","authenticated-orcid":false,"given":"Sirey","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Utah , Salt Lake City, UT ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L","family":"Hersh","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Utah , Salt Lake City, UT ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Mehra","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Utah , Salt Lake City, UT ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6209-1740","authenticated-orcid":false,"given":"Nora","family":"Fino","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Utah Spencer Fox Eccles School of Medicine , Salt Lake City, UT ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3281-9614","authenticated-orcid":false,"given":"Jared","family":"Olson","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Utah , Salt Lake City, UT ,","place":["United States"]},{"name":"Department of Pharmacy, Primary Children\u2019s Hospital , Salt Lake City, UT ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"2026081214013995100_ref1","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jpeds.2018.12.002","article-title":"Risk factors for complications in children with Staphylococcus aureus bacteremia","volume":"208","author":"Hamdy","year":"2019","journal-title":"J Pediatr"},{"key":"2026081214013995100_ref2","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1017\/ice.2018.259","article-title":"Epidemiology of Staphylococcus aureus infections in patients admitted to freestanding pediatric hospitals, 2009-2016","volume":"39","author":"Spaulding","year":"2018","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026081214013995100_ref3","doi-asserted-by":"publisher","first-page":"e1294","DOI":"10.1542\/peds.2009-2867","article-title":"Antibiotic management of Staphylococcus aureus infections in US children's hospitals, 1999-2008","volume":"125","author":"Herigon","year":"2010","journal-title":"Pediatrics."},{"key":"2026081214013995100_ref4","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"2026081214013995100_ref5","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/jpids\/piad032","article-title":"Time for a change: considering vancomycin alternatives for Pediatric methicillin-resistant Staphylococcus aureus bacteremia","volume":"12","author":"Haynes","year":"2023","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2026081214013995100_ref6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/phar.2741","article-title":"Vancomycin plus ceftaroline for persistent methicillin-resistant Staphylococcus aureus bacteremia","volume":"43","author":"Kufel","year":"2023","journal-title":"Pharmacotherapy."},{"key":"2026081214013995100_ref7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40801-024-00422-5","article-title":"Ceftaroline Fosamil for the treatment of methicillin-resistant Staphylococcus aureus bacteremia: a real-world comparative clinical outcomes study","volume":"11","author":"Hammond","year":"2024","journal-title":"Drugs Real World Outcomes"},{"key":"2026081214013995100_ref8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40121-016-0144-8","article-title":"Use of Ceftaroline fosamil in children: review of current knowledge and its application","volume":"6","author":"Yim","year":"2017","journal-title":"Infect Dis Ther"},{"key":"2026081214013995100_ref9","doi-asserted-by":"publisher","first-page":"ofae631.1367","DOI":"10.1093\/ofid\/ofae631.1367","article-title":"P-1181. Comparing the outcomes of ceftaroline versus vancomycin for the treatment of osteomyelitis and septic arthritis in pediatric patients, open forum","volume":"12","author":"Reto","year":"2025","journal-title":"Infectious Diseases"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/advance-article-pdf\/doi\/10.1093\/jpids\/piag065\/70480932\/piag065.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/15\/8\/piag065\/70480932\/piag065.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/15\/8\/piag065\/70480932\/piag065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T18:01:50Z","timestamp":1786557710000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/doi\/10.1093\/jpids\/piag065\/8751159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piag065","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8]]},"article-number":"piag065"}}